A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.

Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B p24, RT, Nef, p17 fusion protein (F4/AS01) plus a non-replicating adenovirus 35 expressing clade A Gag, RT, Int and Nef (Ad35-GRIN) may lead to a unique immune profile, inducing both strong T-cell an...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autori principali:	Gloria Omosa-Manyonyi, Juliet Mpendo, Eugene Ruzagira, William Kilembe, Elwyn Chomba, François Roman, Patricia Bourguignon, Marguerite Koutsoukos, Alix Collard, Gerald Voss, Dagna Laufer, Gwynn Stevens, Peter Hayes, Lorna Clark, Emmanuel Cormier, Len Dally, Burc Barin, Jim Ackland, Kristen Syvertsen, Devika Zachariah, Kamaal Anas, Eddy Sayeed, Angela Lombardo, Jill Gilmour, Josephine Cox, Patricia Fast, Frances Priddy
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Public Library of Science (PLoS) 2015-01-01
Serie:	PLoS ONE
Accesso online:	http://europepmc.org/articles/PMC4427332?pdf=render
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.

Documenti analoghi